Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3JOIX)

Drug Name
BI-754091 Drug Info
Indication
Disease Entry ICD 11 Status REF
Advanced malignancy 2A00-2F9Z Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM3JOIX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Programmed cell death protein 1 (PD-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nivolumab DMAB9QE Melanoma 2C30 Approved [2]
Tislelizumab DMGVUO5 Hodgkin lymphoma 2B30 Approved [3]
MK-3475 DMBYNW0 Melanoma 2C30 Approved [2]
Pembrolizumab DMFQEA6 Melanoma 2C30 Approved [1]
Cemiplimab DMKMJHE Cutaneous squamous cell carcinoma 2C30 Approved [4]
Retifanlimab DMRKTCP Neuroendocrine cancer 2B72.1 Approved [5]
Sintilimab DMGWR0C Hodgkin lymphoma 2B30 Approved [6]
Dostarlimab DM78NWP Endometrial cancer 2C76 Approved [7]
Toripalimab DMSGA6Z Demodex blepharitis 1G07 Approved in China [8]
PDR001 DM53J6B Melanoma 2C30 Phase 3 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Not Available [1]

References

1 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
2 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3 Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
7 Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
8 Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)